Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01615068
Other study ID # ML28257
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 5, 2012
Est. completion date November 16, 2017

Study information

Verified date July 2018
Source Genentech, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.


Recruitment information / eligibility

Status Completed
Enrollment 1007
Est. completion date November 16, 2017
Est. primary completion date November 16, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients, >/=18 years of age

- Initial diagnosis of HER2+ MBC, as diagnosed by the treating physician, no more than 6 months prior to study enrollment

- Availability of cancer-specific historical data points in the patient's medical records

Exclusion Criteria:

- Any inability to provide informed consent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Hendrick Cancer Center Abilene Texas
United States Alton Memorial Hospital; Outpatient Clinic and Infusion Center Alton Illinois
United States McFarland Clinic Ames Iowa
United States Hope A Women's Cancer Center Asheville North Carolina
United States Peachtree Hematology & Oncology Consultants, Pc Atlanta Georgia
United States Mary Bird Perkins Cancer Ctr Baton Rouge Louisiana
United States Medical Oncology LLC Baton Rouge Louisiana
United States Texas Oncology Bedford Texas
United States Summit Medical Group Berkeley Heights New Jersey
United States Billings Clinic Research Center Billings Montana
United States St. Vincent'S Hospital; Birmingham Hematology Oncology Associates, Llc Birmingham Alabama
United States Lynn Cancer Institute - West Boca Raton Florida
United States St. Joseph Regional Cancer Ct Bryan Texas
United States East Valley Hem/Onc Med Group; Metropolitan Hem Onc. Burbank California
United States South Bay Oncology Hematology Partners Campbell California
United States Charleston Hematology Oncology Charleston South Carolina
United States Medical Univ of South Carolina Charleston South Carolina
United States Chattanooga Oncology and Hematology Associates, PC Chattanooga Tennessee
United States Rush University Medical Center Chicago Illinois
United States Metro Health Medical Center Cleveland Ohio
United States South Carolina Oncology Associates - SCRI Columbia South Carolina
United States Mid Ohio Onc Hematology Inc Columbus Ohio
United States The Mary Imogene Bassett Hospi Cooperstown New York
United States Western Maryland Health Sys Cumberland Maryland
United States Texas Oncology-Baylor Sammons Cancer Center Dallas Texas
United States University of Miami; Dept Sylvester Cancer Center Deerfield Beach Florida
United States Kaiser Permanente Of Colorado Denver Colorado
United States Rocky Mountain Cancer Center - Denver Denver Colorado
United States Onc & Hematology Specialists Denville New Jersey
United States Hematology & Oncology Assoc; North Eastern Pennsylvania Dunmore Pennsylvania
United States North Shore Hem Onc Associates East Setauket New York
United States Southdale Cancer Clinic U of M Medical Center, Fairview- Edina Edina Minnesota
United States Texas Oncology- El Paso Cancer Treatment Center Gateway El Paso Texas
United States California Cancer Associates for Research & Excellence, Inc. Encinitas California
United States Oncology Hematology Assoc Evansville Indiana
United States Florida Cancer Specialists - Fort Myers (New Hampshire Ct) Fort Myers Florida
United States Texas Oncology, P.A. - Fort Worth Fort Worth Texas
United States ROBERT A. MOSS, M.D., F.A.C.P., Inc Fountain Valley California
United States California Oncology of the Central Valley Fresno California
United States Cancer Care Associates Fresno California
United States St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr Fullerton California
United States Gaston Hematology/Oncology Gastonia North Carolina
United States Cancer & Hematology Centers of Western Michigan Grand Rapids Michigan
United States Cone Health Cancer Center Greensboro North Carolina
United States Hackensack University Medical Center Hackensack New Jersey
United States Memorial Cancer Institute Hollywood Florida
United States Genesis Cancer Center Hot Springs Arkansas
United States Texas Oncology - Houston (Gessner) Houston Texas
United States University of Iowa Iowa City Iowa
United States Jackson Oncology Associates, PLLC Jackson Mississippi
United States Baptist - MD Anderson Cancer Center Jacksonville Florida
United States Florida Oncology Associates Jacksonville Florida
United States Queens Hospital Center Jamaica New York
United States Jefferson City Medical Group Jefferson City Missouri
United States NEA Baptist Clinic Jonesboro Arkansas
United States West Michigan Cancer Center Kalamazoo Michigan
United States Research Medical Center; Pharmacy Kansas City Missouri
United States Kingsport Hematology Oncology Associates Kingsport Tennessee
United States Center for Biomedical Research LLC Knoxville Tennessee
United States Lafayette General Medical Center Lafayette Louisiana
United States Lakeland Regional Cancer Center Lakeland Florida
United States Lancaster Cancer Center, Ltd. Lancaster Pennsylvania
United States Comprehensive Cancer Centers of Nevada Las Vegas Nevada
United States Dartmouth Hitchcock Medical Center; Gastroenterology Section Lebanon New Hampshire
United States Southeast Nebraska Cancer Center;; Southeast Nebraska Hematology and Oncology Lincoln Nebraska
United States Hematology Oncology Services of Arkansas Little Rock Arkansas
United States Mile High Oncology Littleton Colorado
United States UCLA School of Medicine Los Angeles California
United States University of Southern California Los Angeles California
United States Baptist Hospital East Louisville Kentucky
United States James Graham Brown Cancer Center, University of Louisville Louisville Kentucky
United States Southeastern Regional Medical Center Lumberton North Carolina
United States Lynchburg Hem Onc Clinic Inc Lynchburg Virginia
United States University of Wisconsin Madison Wisconsin
United States Northwest Georgia Oncology Centers PC - Marietta Marietta Georgia
United States Mercy Medical Ctr-North Iowa ; Mercy Cancer Center Mason City Iowa
United States Texas Oncology, P.A. - McAllen; South Texas Cancer Center-McAllen McAllen Texas
United States Connecticut Oncology Group Middletown Connecticut
United States Signal Point Clinical; Research Center, LLC Middletown Ohio
United States Columbia Saint Mary's; Medical Oncology Milwaukee Wisconsin
United States Minnesota Oncology Hematology, Pa Minneapolis Minnesota
United States Montana Cancer Specialists Missoula Montana
United States University of South Alabama; Mitchell Cancer Institute Mobile Alabama
United States West Virginia University Hospitals Inc Morgantown West Virginia
United States Hematology Oncology Associates; Carol G. Simon Ctr Morristown New Jersey
United States Boston Baskin Cancer Foundation Nashville Tennessee
United States Sarah Cannon Research Inst. Nashville Tennessee
United States Yale Cancer Center New Haven Connecticut
United States Beth Israel Comprehensive Cancer Center Pharmacy New York New York
United States Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion New York New York
United States Peninsula Cancer Institute Newport News Virginia
United States Mid-Illinois Hematology Normal Illinois
United States Northern Utah Associates Ogden Utah
United States Mercy Clinic Oklahoma Communties, Inc Oklahoma City Oklahoma
United States Cancer Alliance of Nebraska Omaha Nebraska
United States Md Anderson Cancer Center Orlando Orlando Florida
United States Comprehensive Cancer Care Palm Springs California
United States Luckow Pavillion, Valley Hosp; Office of Clinical Trials Paramus New Jersey
United States Texas Oncology - Paris Paris Texas
United States Oncology Specialists, S.C. Park Ridge Illinois
United States Temple University Hospital Philadelphia Pennsylvania
United States First Health of the Carolinas Pinehurst North Carolina
United States Allegheny General Hospital; Transplantation Services Pittsburgh Pennsylvania
United States Univ of Pittsburgh Sch of Med; Magee-Womens Hospital Pittsburgh Pennsylvania
United States Berkshire Hematology, Oncology Pc Pittsfield Massachusetts
United States Florida Cancer Research Institute Plantation Florida
United States Mercy Oncology / Hematology Center; Oncology Portland Maine
United States Providence Cancer Center Portland Oregon
United States Portsmouth Regional Hospital; Hem/Onc Clinic Portsmouth New Hampshire
United States Kootenai Cancer Center Post Falls Idaho
United States Virginia Cancer Institute Richmond Virginia
United States Associates in Oncology/Hematology P.C. Rockville Maryland
United States Highlands Oncology Group Rogers Arkansas
United States Christian Hospital; Outpatient Cancer and Infusion Center Saint Louis Missouri
United States St. John'S Mercy Medical Center; David C. Pratt Cancer Center Saint Louis Missouri
United States Park Nicollet Clinic Cancer Center Saint Louis Park Minnesota
United States Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building) Saint Petersburg Florida
United States Huntsman Cancer Institute; Oncology Salt Lake City Utah
United States Univ of Calif, San Francisco; Breast Cancer Center San Francisco California
United States Coastal Integrative Cancer Care San Luis Obispo California
United States Central Coast Medical Oncology Santa Maria California
United States Sutter Pacific Medical Foundation Santa Rosa California
United States Summit Cancer Care PC Savannah Georgia
United States Guthrie Clinic Sayre Pennsylvania
United States Virginia Mason Medical Center Seattle Washington
United States Arizona Oncology Associates, PC - NAHOA Sedona Arizona
United States Capitol Hematology & Oncology Silver Spring Maryland
United States Orchard Healthcare Research Inc. Skokie Illinois
United States Hematology Oncology P.C. Stamford Connecticut
United States Flower Memorial Hospital Sylvania Ohio
United States Space Coast Medical Associates Titusville Florida
United States St. Joseph Medical Center Towson Maryland
United States Arizona Oncology Tucson Arizona
United States Cancer Care Assoc-15th St Tulsa Oklahoma
United States Tyler Hematololgy Oncology, PA Tyler Texas
United States Carle Cancer Center Urbana Illinois
United States Texas Oncology, PA Waco Texas
United States MedStar Washington Hosp Center Washington District of Columbia
United States Texas Oncology, P.A.; Duke Slayton Cancer Center Webster Texas
United States Carroll County Cancer Center Westminster Maryland
United States Cancer Center of Kansas Wichita Kansas
United States Shenandoah Oncology Associates Winchester Virginia

Sponsors (1)

Lead Sponsor Collaborator
Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Distribution of patients receiving unique treatment regimen/sequence of treatment regimens Up to 8 years
Secondary Progression-free survival (PFS) Up to 8 years
Secondary Overall survival (OS) Up to 8 years
Secondary Post-progression survival (PPS) Up to 8 years
Secondary Time-to-treatment failure (TTF) Up to 8 years
Secondary Response rate (RR) Up to 8 years
Secondary Safety: Incidence of adverse events Up to 8 years
Secondary Patient-reported outcome assessment (PRO) Up to 8 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2